Skip to content
News Center
About Us Careers News Center Contact Us Legal Doing Business with Illumina Investors Illumina for Startups Customer Engagement Center

Corporate

Video: Illumina Breaks Ground in UK

UK minister leads ceremony of new EMEA HQ

Illumina Breaks Ground in UK
October 21, 2015

Illumina, Inc. reached an exciting milestone as it held a VIP ground breaking ceremony at the site of its new Europe, Middle East and Africa HQ at Granta Park in Cambridge. Special guest speaker, the UK Minister for Life Sciences, George Freeman, welcomed the investment being made by Illumina in the UK.   

Previous Article
Next Article

Recent articles

Hunting for hidden clues in the human genome’s “dark regions”
Hunting for hidden clues in the human genome’s “dark regions”
How Illumina employees work to move healthcare toward precision medicine
How Illumina employees work to move healthcare toward precision medicine
Multiomics help separate malignant and benign tumors in tricky ovarian cases
Multiomics help separate malignant and benign tumors in tricky ovarian cases
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.